Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Meissa Vaccines

Request full access

Meissa vaccines develops vaccines to protect people from life-threatening respiratory viruses

San Francisco, United StatesFounded 2014Biotech & Life Sciences

About Meissa Vaccines

Meissa Vaccines is a pharmaceutical startup dedicated to developing vaccines for serious human diseases, particularly respiratory syncytial virus (RSV) and rhinovirus. The company leverages innovative platform technology for viral genetic engineering, which can be applied to multiple pathogens. Meissa's primary focus is on child health, but its vaccine programs have the potential to benefit various age and population groups. The successful development of vaccines for RSV and related viruses promises widespread societal benefits, including alleviating serious lower respiratory tract diseases and reducing asthma and COPD exacerbations. Meissa operates in the pharmaceutical and biotech sectors, serving healthcare providers, hospitals, and potentially global health organizations. The business model revolves around research and development, clinical trials, and eventual commercialization of vaccines. Revenue is generated through partnerships, grants, and future sales of approved vaccines.

Source: Dealroom company data

At a glance

Status
Operational
Employees
3
Open positions
None listed
Dealroom signal
56.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Vaccines, Synthetic Biology, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Sep 2019 $30M $120M Morningside —
SEED✓Equity / VC Mar 2019 $3.4M $14M Undisclosed —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Meissa Vaccines website traffic

Latest recorded traffic for Meissa Vaccines is 380 monthly website visits, up 31% over the last three months. Meissa Vaccines's team grew 0% over the past year.

Latest monthly visits380 3-month web change+31% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Meissa Vaccines in the San Francisco ecosystem

Live from Dealroom

The Meissa Vaccines office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • FundRx

Series A1 investor entered at this stage

Other known investors1 additional known investor

  • Emory University
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Francisco HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Meissa Vaccines on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Meissa Vaccines’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.